Abstract 3274
Background
Little is known regarding the efficacy of ICPi in LCNET.
Methods
Thirty seven consecutive patients (pts) with advanced LCNET were selected from the Davidoff Cancer Center database. These were divided into Groups A1 (pts treated with ICPi, n-23) and A2 (pts not treated with ICPi, n-14). Another cohort of advanced non-small cell lung cancer (NSCLC) pts treated with nivolumab at five Israeli cancer centers in 2015-2016 was chosen as a comparator (Group B, n-270). ORR, PFS with ICPi in Group A1 were assessed (RECIST 1.1), OS with ICPi was compared between Groups A1 and B. OS since advanced disease diagnosis (OSDx) was compared between Groups A1 and A2.
Results
Baseline pts characteristics are presented in the table. In Group A1* (n-21, 2 pts receiving combined ICPi + chemotherapy were excluded), ORR and median PFS with ICPi were 33%, and 4.2 months (95% CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in Groups A1* and B, respectively, 52% of pts in Group A1* and 64% of pts in Group B had died. Median OS with ICPi comprised 11.8 months (95% CI, 3.7-NR) and 6.9 months (95% CI, 5.5-8.1) in Groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95% CI, 10.1-38.9) and 10.3 months (95% CI, 2.6-NR), in Groups A1 and A2, respectively (p-0.54). Abbreviations: Tx- treatment, N – nivolumab, P-pembrolizumab, A- atezolizumab.Table: 1403P Baseline patients characteristics
Group A1* (n-21) | Group B (n-270) | p value | |
---|---|---|---|
Age (median, range), y | 62 (45-77) | 67 (40-99) | 0.004 |
Gender, % | 0.09 | ||
F | 52 | 33 | |
M | 48 | 67 | |
Smoking, % | 1 | ||
Smokers | 86 | 77 | |
Never smokers | 14 | 14 | |
NA | 9 | ||
ECOG PS at ICPi, % | 0.06 | ||
0/1 | 67 | 46 | |
2-4 | 24 | 47 | |
NA | 9 | 7 | |
Previous Tx lines, % | 0.2 | ||
0 | 10 | 6 | |
1 | 80 | 66 | |
2-4 | 10 | 25 | |
NA | 10 (3) | ||
ICPi type: N/P/A/other, % | 62/9/20/9 | 100/0/0/0 | NA |
Conclusions
In advanced LCNET, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future prospective research is needed to clarify the impact of ICPi on OS in LCNET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Zer: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca, Roche, BMS, MSD, BI, TAKADA. E. Dudnik: Research grant / Funding (self): Roche, Boehringer Ingelheim; Advisory / Consultancy: Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD, BMS, Novartis, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
2780 - A phase 3, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
Presenter: Do-Youn Oh
Session: Poster Display session 2
Resources:
Abstract
4413 - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial
Presenter: Ghassan Abou-Alfa
Session: Poster Display session 2
Resources:
Abstract
4710 - Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Lorenza Rimassa
Session: Poster Display session 2
Resources:
Abstract
5509 - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)
Presenter: Li-Tzong Chen
Session: Poster Display session 2
Resources:
Abstract
1463 - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Presenter: Sylvie Lorenzen
Session: Poster Display session 2
Resources:
Abstract
2392 - GLOW: Randomized Phase 3 Study of Zolbetuximab + CAPOX Compared With Placebo + CAPOX as First-line Treatment of Patients With CLD18.2⁺/HER2⁻ Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Manish Shah
Session: Poster Display session 2
Resources:
Abstract
5217 - PRODIGE67_UCGI33 ARION: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial
Presenter: Rosine Guimbaud
Session: Poster Display session 2
Resources:
Abstract
1726 - Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT
Presenter: Kenro Hirata
Session: Poster Display session 2
Resources:
Abstract
2279 - FRONTiER: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
Presenter: Shun Yamamoto
Session: Poster Display session 2
Resources:
Abstract
4912 - A phase Ib/II study of AK104, a PD-1/CTLA-4 Bispecific Antibody, Combined With mXELOX as First-line Therapy for Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Presenter: Jiafu Ji
Session: Poster Display session 2
Resources:
Abstract